To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: A systematic review
Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; Clinician Investigator Program, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
Show others and affiliations
2017 (English)In: Frontiers in Neurology, E-ISSN 1664-2295, Vol. 8, article id 300Article, review/survey (Refereed) Published
Abstract [en]

Background: The proteins S100B, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and neurofilament light (NF-L) have been serially sampled in serum of patients suffering from traumatic brain injury (TBI) in order to assess injury severity and tissue fate. We review the current literature of serum level dynamics of these proteins following TBI and used the term "effective half-life" (t1/2) in order to describe the "fall" rate in serum.

Materials and methods: Through searches on EMBASE, Medline, and Scopus, we looked for articles where these proteins had been serially sampled in serum in human TBI. We excluded animal studies, studies with only one presented sample and studies without neuroradiological examinations.

Results: Following screening (10,389 papers), n = 122 papers were included. The proteins S100B (n = 66) and NSE (n = 27) were the two most frequent biomarkers that were serially sampled. For S100B in severe TBI, a majority of studies indicate a t1/2 of about 24 h, even if very early sampling in these patients reveals rapid decreases (1-2 h) though possibly of non-cerebral origin. In contrast, the t1/2 for NSE is comparably longer, ranging from 48 to 72 h in severe TBI cases. The protein GFAP (n = 18) appears to have t1/2 of about 24-48 h in severe TBI. The protein UCH-L1 (n = 9) presents a t1/2 around 7 h in mild TBI and about 10 h in severe. Frequent sampling of these proteins revealed different trajectories with persisting high serum levels, or secondary peaks, in patients with unfavorable outcome or in patients developing secondary detrimental events. Finally, NF-L (n = 2) only increased in the few studies available, suggesting a serum availability of >10 days. To date, automated assays are available for S100B and NSE making them faster and more practical to use.

Conclusion: Serial sampling of brain-specific proteins in serum reveals different temporal trajectories that should be acknowledged. Proteins with shorter serum availability, like S100B, may be superior to proteins such as NF-L in detection of secondary harmful events when monitoring patients with TBI.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2017. Vol. 8, article id 300
Keywords [en]
S100B, biomarkers, glial fibrillary acidic protein, neurofilament light, neuron-specific enolase, serum, traumatic brain injury, ubiquitin carboxy-terminal hydrolase L1
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-113604DOI: 10.3389/fneur.2017.00300ISI: 000404505900001PubMedID: 28717351Scopus ID: 2-s2.0-85022228912OAI: oai:DiVA.org:oru-113604DiVA, id: diva2:1857765
Funder
Swedish Society of Medicine, SLS-587221
Note

Funidng Agencies:

Cambridge Commonwealth Trust Scholarship

Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery

University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award

Manitoba Medical Service Foundation

University of Manitoba Faculty of Medicine Dean's Fellowship Fund

Hungarian Brain Research ProgramKTIA_13_NAP-A-II/8

National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award

European Union (EU)

Marie Curie Actions

UK Research & Innovation (UKRI)

Medical Research Council UK (MRC)

Cambridge Biomedical Research Centre

Royal College of Surgeons of England

National Institutes of Health Research (NIHR)

Available from: 2024-05-14 Created: 2024-05-14 Last updated: 2024-05-20Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Büki, Andras

Search in DiVA

By author/editor
Büki, Andras
In the same journal
Frontiers in Neurology
Neurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 7 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf